Plus therapeutics reports third quarter 2024 financial results and recent business highlights

Obtained agreement from fda to initiate a phase 1 trial evaluating multiple doses of rhenium ( 186 re) obisbemeda for the treatment of patients with leptomeningeal metastases (lm) presented positive respect-gbm trial data at the 2024 congress of neurological surgeons annual conference established radiotherapeutic manufacturing partnership with spectronrx to meet late-stage clinical and commercial forecasts for rhenium ( 186 re) obisbemeda austin, texas, nov. 14, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announced financial results for the third quarter ended september 30, 2024, and provided an overview of recent and upcoming business highlights. q3 2024 recent highlights and milestones completed enrollment in the phase 1 respect-gbm trial obtained agreement from fda to begin enrollment in the respect-lm multi-administration trial for patients with lm (ind 153715).
pstv Ratings Summary
pstv Quant Ranking